SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44, to be conducted with LabCorp. The studies are designed to assess safety, dosing parameters and biomarkers across multiple species, supporting future Phase I clinical trials for the GLP-1 agonist peptide targeting Type II diabetes and obesity.
The advancement of GEP-44 into IND-enabling studies marks a critical step for SureNano as it transitions from a surfactant distributor to a pharmaceutical-focused company. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. Obesity and diabetes represent massive global health markets, and GLP-1 agonists have become blockbuster therapies. SureNano's candidate aims to differentiate itself through better tolerability and alternative delivery methods.
Alongside the scientific progress, SureNano outlined expanded investor outreach initiatives. The company has entered into a strategic agreement with Investor Brand Network (IBN) to leverage its syndication network of more than 5,000 media outlets. This partnership is intended to strengthen market awareness and support continued advancement of its therapeutic pipeline. The company also disclosed additional marketing engagements and early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies.
For investors, the dual focus on clinical milestones and investor communications signals management's commitment to building long-term value. The IND-enabling studies with a contract research organization like LabCorp lend credibility to the development process. Meanwhile, the expanded media outreach through IBN's network could increase visibility among potential partners and investors.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with high growth potential. The initial business of the company is the sale and distribution of the SureNano surfactant, but the company is now developing into a pharmaceutical-focused entity through the advancement of GEP-44. The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF.
The full press release can be viewed at https://ibn.fm/a6nGj.